A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

NCT04933825 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Interventions

BIOLOGICAL: ET-02

Sponsor

EdiGene (GuangZhou) Inc.

Collaborators

[object Object]